Takeda In Hot Pursuit Of Zika Vaccine With $312m US Contract

Takeda is officially in the ballgame, joining the ranks of other firms like Sanofi Pasteur and GlaxoSmithKline, to find a vaccine against the Zika virus after snagging a US government R&D contract worth up to $312m.

Zika virus

Takeda Pharmaceutical Co. Ltd. has jumped fully into development of a Zika vaccine after landing a US government contract worth up to $312m that will fund the Japanese biopharmaceutical firm's efforts.

Takeda has banked $19.8m from the US Biomedical Advanced Research and Development Authority (BARDA) to get the ball rolling on...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anti-infective

More from Therapeutic Category